Geschäftsbericht der Lindenhofgruppe 2019

Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperations- partner /  Sponsor Eribulin as 1st line treatment in elderly patients (≥70 years) with advanced breast cancer (SAKK25/14) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Schweizerische Arbeitsgemein- schaft für Klini- sche Krebsfor- schung, Campus Stiftung Linden- hof Bern (SLB) Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 in patients with bone metastases from castration resistant prostate cancer or from breast cancer (SAKK 96/12 REDUSE) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Schweizerische Arbeitsgemein- schaft für Klini- sche Krebsfor- schung, Campus Stiftung Linden- hof Bern (SLB) A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer (IBCSG 35-07 BIG 1-07 SOLE) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group, Campus Stiftung Lindenhof Bern (SLB) A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer tamoxifen versus ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (IBCSG 24-02 BIG 2-02 SOFT) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group, Campus Stiftung Lindenhof Bern (SLB) A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (IBCSG 25-02 BIG 3-02 TEXT) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group, Campus Stiftung Lindenhof Bern (SLB) Helping Ourselves, Helping Others: The Young Women’s Breast Cancer Study (IBCSG 43-09 HoHo) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group, Campus Stiftung Lindenhof Bern (SLB) Geschäftsbericht 2019 76 Lehre und Forschung